Back to discover
Disease

Lennox-Gastaut syndrome

Late-stage therapeutic development
Also known as LGS, Lennox syndrome, encephalopathy of childhood, epileptic encephalopathy Lennox-Gastaut type+1 more

LGS, Lennox syndrome, encephalopathy of childhood, epileptic encephalopathy Lennox-Gastaut type, macrocephaly and epileptic encephalopathy.

12
Clinical trials
12
Associated genes
10
Related proteins
Current focus
Cannabinoid 1 biologyGlutamate 2 biologyTherapeutic development

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

No activity recorded in this window. Try a wider timeframe.

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Fenfluramine hydrochlorideapproved

Approval — Treatment of seizures associated with Dravet syndrome as an add-on therapy to other antie… (2020)

Cannabidiolapproved

Approval — Epidyolex is indicated for use as adjunctive therapy of seizures associated with Lennox G… (2019)

Rufinamideapproved

Approval — Inovelon is indicated as adjunctive therapy in the treatment of seizures associated with… (2007)

Clinical trials

7 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
12
All trials
0
Active
12
Late-stage
6
Completed
Late-stage studies

An Open Label Extension Study to Investigate the Safety of Cannabidiol (GWP42003-P; CBD) in Children and Adults With Inadequately Controlled Dravet or Lennox-Gastaut Syndromes.

Phase 3 · Completed · GW Research Ltd

A Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Cognitive Development Effects and Safety, and Pharmacokinetics of Adjunctive Rufinamide Treatment in Pediatric Subjects 1 to Less Than 4 Years of Age With Inadequately Controlled Lennox-Gastaut Syndrome

Phase 3 · Completed · Eisai Inc.

A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults.

Phase 3 · Completed · Jazz Pharmaceuticals

A Long Term Extension Study of E2080 in Lennox-Gastaut Patients

Phase 3 · Completed · Eisai Co., Ltd.

An Open-label, Single-arm Study to Assess the Safety, Pharmacokinetics, and Efficacy of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Participants With Tuberous Sclerosis Complex (Age 1 Month to < 2 Years of Age), Dravet Syndrome (1 Year to < 2 Years of Age), or Lennox-Gastaut Syndrome (1 Year to < 2 Years of Age) Who Experience Inadequately-controlled Seizures

Phase 3 · Terminated · Jazz Pharmaceuticals

An Open-label, Nonrandomized, Phase 3 Study to Evaluate the Efficacy and Safety of Soticlestat in Participants With Dravet Syndrome or Lennox-Gastaut Syndrome Who Have Been Exposed to Fenfluramine

Phase 3 · Terminated · Takeda
Recently completed

An Open Label Extension Study to Investigate the Safety of Cannabidiol (GWP42003-P; CBD) in Children and Adults With Inadequately Controlled Dravet or Lennox-Gastaut Syndromes.

Phase 3 · Completed · GW Research Ltd

A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults.

Phase 3 · Completed · Jazz Pharmaceuticals

A Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Cognitive Development Effects and Safety, and Pharmacokinetics of Adjunctive Rufinamide Treatment in Pediatric Subjects 1 to Less Than 4 Years of Age With Inadequately Controlled Lennox-Gastaut Syndrome

Phase 3 · Completed · Eisai Inc.

A Long Term Extension Study of E2080 in Lennox-Gastaut Patients

Phase 3 · Completed · Eisai Co., Ltd.

Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome

Phase 3 · Completed · Lundbeck LLC

A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients

Phase 3 · Completed · Eisai Limited

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2020emaApproval — Fenfluramine hydrochloride· Treatment of seizures associated with Dravet syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older. Fintepla is indicated for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older. source ↗
2019emaApproval — Cannabidiol· Epidyolex is indicated for use as adjunctive therapy of seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome (DS), in conjunction with clobazam, for patients 2 years of age and older. source ↗
2007emaApproval — Rufinamide· Inovelon is indicated as adjunctive therapy in the treatment of seizures associated with Lennox Gastaut syndrome in patients 4 years of age and older. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Associated genes

12 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

DNM10.73SCN1A0.68GABRB30.67GABRG20.66SCN11A0.60CNR10.57GRIA20.54GRIA40.54GRIK10.53GRIK20.53CIZ10.51CUX20.38

Disease biology

10 matches

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Sodium channel protein type 1 subunit alphavia SCN1A0.68Gamma-aminobutyric acid receptor subunit beta-3via GABRB30.67Gamma-aminobutyric acid receptor subunit gamma-2via GABRG20.66Sodium channel protein type 11 subunit alphavia SCN11A0.60Cannabinoid receptor 1via CNR10.57Glutamate receptor 2via GRIA20.54Glutamate receptor 4via GRIA40.54Glutamate receptor ionotropic, kainate 1via GRIK10.53Glutamate receptor ionotropic, kainate 2via GRIK20.53Mitogen-activated protein kinase 10via MAPK100.27

Reference

Authoritative identity, definition & identifiers.

Synonyms

LGS, Lennox syndrome, encephalopathy of childhood, epileptic encephalopathy Lennox-Gastaut type, macrocephaly and epileptic encephalopathy

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.